About Palisade Bio Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://palisadebio.com/
Frequently Asked Questions
What is the 52-week range for PALI?
The 52-week high is $2.855 and the 52-week low is $0.96.
What is the P/E ratio for PALI?
The P/E ratio data is currently unavailable.
What is the dividend yield for PALI?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -33.47%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -2114.80%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.71.
Analyst Recommendation Trends
Wall Street analyst consensus for PALI over the last few months:
Latest PALI News
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026
Oral presentation to highlight early endoscopic improvement and evidence of PDE4 target engagement in fibrostenotic Crohn’s disease Three moderated posters to showcase gut-targeted exposure, favorable safety and tolerability, rapid clinical response in ulcerative colitis, and the development of a biomarker to predict treatment response Denver, CO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company develop
Palisade Bio To Present Four Presentations At United European Gastroenterology Week 2026 For Its PALI-2018 Program
Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases,
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s
Palisade Bio (NASDAQ:PALI) said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn’s disease after completing its Phase I program. Chief Executive Officer JD Finley said PALI-2108 is a once-daily oral phosphodiesterase 4, or PDE4, inhibitor de
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
Canadian clearance supports site activation and enrollment in the global study of once-daily oral PALI-2108 Primary efficacy results from approximately 204 patients with moderately to severely active ulcerative colitis expected in the second half of 2027 Denver, CO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic dis
Palisade Bio Receives Health Canada's Clearance For Its Clinical Trial Application For ASCENTRA-UC Trial Of PALI-2108 To Treat Severely Active Ulcerative Colitis
Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic
HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Palisade Bio (NASDAQ:PALI) with a Buy and maintains $7 price target.
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD
Palisade Bio, Inc. Phase 2 ASCENTRA-CD clinical trial in patients with moderate to severe Crohn’s disease (CD) ASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn’s disease First patient dosing targeted for Q1 2027; primary efficacy readout (Week 12 endoscopic response) targeted for Q1 2028 Phase 2 program builds on clinical experience in fibrostenotic Crohn’s disease demonstrating targeted tissue exposure, PDE4 target engagement and encouraging endoscopic acti
Palisade Bio Receives FDA Clearance For Its Investigational New Drug Application For PALI-2108 To Treat Crohn's Disease; First Participant Enrollment Anticipated In Q1 Next Year
Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases,
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
Presentation scheduled for September 23, 2026 at 1:00 PM ET Access the webcast here Denver, CO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that JD Finley, Chief Executive Officer, and Mitchell Jones, M.D., Ph.D., President and Chief Medical Officer, will participate in the Stifel 2026 V
Palisade Bio, Inc. (PALI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Palisade Bio, Inc. (PALI) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 10:00 AM EDTCompany ParticipantsJ.
ServiceTitan, Braze, Target Hospitality And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. futures were mixed; ServiceTitan plunged 16.7% on weak Q3 guidance, while Mind Technology, Braze and others also fell premarket.
Palisade Bio to Participate in Upcoming Investor Conferences
Denver, CO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that members of management will participate in three healthcare investor conferences in September 2026. Wells Fargo 2026 Healthcare Conference Dates: September 8–10, 2026Location: Boston, MassachusettsFormat: Investor meetings Morga
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-19 | Finley John David | +88,400 | - | - |
| 2026-08-19 | Finley John David | -88,400 | - | - |
| 2026-07-09 | Baltera Robert Jr. | +25,000 | $1.956 | $48,900 |
| 2026-07-08 | Baltera Robert Jr. | +20,000 | $1.9899 | $39,798 |
| 2026-07-07 | Baltera Robert Jr. | +30,000 | $2.0348 | $61,044 |
| 2026-07-07 | Jones Mitchell Lawrence | -51,880 | $2.0535 | $106,536 |
| 2026-07-07 | Finley John David | -133 | - | - |
| 2026-07-07 | Finley John David | +133 | $0.7 | $93 |
| 2026-07-07 | Finley John David | -146,798 | $2.0664 | $303,343 |
| 2026-07-06 | Baltera Robert Jr. | +20,000 | $2.052 | $41,040 |
| 2026-07-06 | Jones Mitchell Lawrence | -131,167 | - | - |
| 2026-07-06 | Jones Mitchell Lawrence | +131,167 | - | - |
| 2026-07-06 | Finley John David | -335,167 | - | - |
| 2026-07-06 | Finley John David | +335,167 | - | - |
| 2026-07-02 | Baltera Robert Jr. | +10,000 | $1.98 | $19,800 |
| 2026-07-01 | Baltera Robert Jr. | +20,000 | $1.98 | $39,600 |
| 2026-06-10 | Baltera Robert Jr. | +336,904 | - | - |
| 2026-06-10 | Wei Binxian | -20,200 | - | - |
| 2026-06-10 | Wei Binxian | +20,200 | - | - |
| 2026-06-10 | Wei Binxian | +592,300 | - | - |
| 2026-06-10 | Williams Donald Allen | -60,666 | - | - |
| 2026-06-10 | Williams Donald Allen | +60,666 | - | - |
| 2026-06-10 | Williams Donald Allen | +1,498,900 | - | - |
| 2026-06-10 | Chuang Emil | -20,200 | - | - |
| 2026-06-10 | Chuang Emil | +20,200 | - | - |
| 2026-06-10 | Chuang Emil | +592,300 | - | - |
| 2026-06-10 | Zwick Jordan Michael | +336,904 | - | - |
| 2026-02-12 | Jones Mitchell Lawrence | -1,989 | $1.75 | $3,481 |
| 2026-02-12 | Finley John David | -3,896 | $1.75 | $6,818 |
| 2026-02-11 | Jones Mitchell Lawrence | -8,000 | - | - |
| 2026-02-11 | Jones Mitchell Lawrence | +8,000 | - | - |
| 2026-02-11 | Finley John David | -13,333 | - | - |
| 2026-02-11 | Finley John David | +13,333 | - | - |
| 2026-02-09 | Jones Mitchell Lawrence | +787,000 | - | - |
| 2026-02-09 | Finley John David | +2,011,000 | - | - |
| 2026-01-16 | Williams Donald Allen | +5,000 | $1.6712 | $8,356 |
| 2026-01-09 | Williams Donald Allen | +5,000 | $1.88 | $9,400 |
| 2025-10-06 | Williams Donald Allen | +182,000 | - | - |
| 2025-10-06 | Wei Binxian | +60,600 | - | - |
| 2025-10-06 | Chuang Emil | +60,600 | - | - |
| 2025-10-06 | Williams Donald Allen | +1,538,700 | - | - |
| 2025-10-06 | Wei Binxian | +510,700 | - | - |
| 2025-10-06 | Jones Mitchell Lawrence | +7,665,800 | - | - |
| 2025-10-06 | Finley John David | +9,179,400 | - | - |
| 2025-10-06 | Chuang Emil | +510,700 | - | - |